Amicus Therapeutics, Inc. (FOLD) Q4 2010 Earnings Results

Amicus Therapeutics Misses on EPS, Stock Up 4.52%

Amicus Therapeutics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 4.52%, likely driven by optimism about ongoing projects and the lack of negative surprises in other areas. Investors may be reacting to the potential of the company's pipeline despite the disappointing EPS figure.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.48	N/A	-215.79%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding future performance. They highlighted ongoing projects but did not offer specific guidance.

Management did not provide specific guidance for future quarters.

The company is focusing on its ongoing projects and pipeline.

Amicus Therapeutics Misses on EPS, Stock Up 4.52%

Key numbers

Management commentary

Amicus Therapeutics, Inc.

More earnings this week

Amicus Therapeutics Misses on EPS, Stock Up 4.52%

Key numbers

Management commentary